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rimary Results of the Rapid Emergency
epartment Heart Failure Outpatient Trial (REDHOT)
Multicenter Study of B-Type Natriuretic Peptide Levels,
mergency Department Decision Making, and
utcomes in Patients Presenting With Shortness of Breath
lan Maisel, MD,* Judd E. Hollander, MD,† David Guss, MD,‡ Peter McCullough, MD, MPH,§
ichard Nowak, MD, Gary Green, MD,¶ Mitchell Saltzberg, MD,# Stefanie R. Ellison, MD, FACEP,§
eenakshi Awasthi Bhalla, MD,* Vikas Bhalla, MD,* Paul Clopton, MS,* Robert Jesse, MD,**
or the REDHOT Investigators
an Diego, California; Philadelphia, Pennsylvania; Kansas City, Missouri; Detroit, Michigan;
altimore, Maryland; Downers Grove, Illinois; and Richmond, Virginia
OBJECTIVES The purpose of this study was to examine the relationships among B-type natriuretic peptide
(BNP) levels within the diagnostic range, perceived congestive heart failure (CHF) severity,
clinical decision making, and outcomes of the CHF patients presenting to emergency
department (ED).
BACKGROUND Since BNP correlates with the presence of CHF, disease severity, and prognosis, we
hypothesized that BNP levels in the diagnostic range offer value independent of physician
decision making with regard to critical outcomes in emergency medicine.
METHODS The Rapid Emergency Department Heart failure Outpatient Trial (REDHOT) study was a
10-center trial in which patients seen in the ED with shortness of breath were consented to
have BNP levels drawn on arrival. Entrance criteria included a BNP level 100 pg/ml.
Physicians were blinded to the actual BNP level and subsequent BNP measurements. Patients
were followed up for 90 days after discharge.
RESULTS Of the 464 patients, 90% were hospitalized. Two-thirds of patients were perceived to be New
York Heart Association (NYHA) functional class III or IV. The BNP levels did not differ
significantly between patients who were discharged home from the ED and those admitted
(976 vs. 766, p  0.6). Using logistic regression analysis, an ED doctor’s intention to admit
or discharge a patient had no influence on 90-day outcomes, while the BNP level was a strong
predictor of 90-day outcome. Of admitted patients, 11% had BNP levels 200 pg/ml (66%
of which were perceived NYHA functional class III or IV). The 90-day combined event rate
(CHF visits or admissions and mortality) in the group of patients admitted with BNP 200
pg/ml and 200 pg/ml was 9% and 29%, respectively (p  0.006).
CONCLUSIONS In patients presenting to the ED with heart failure, there is a disconnect between the perceived
severity of CHF by ED physicians and severity as determined by BNP levels. The BNP levels can
predict future outcomes and thus may aid physicians in making triage decisions about whether to
admit or discharge patients. Emerging clinical data will help further refine biomarker-guided
outpatient therapeutic and monitoring strategies involving BNP. (J Am Coll Cardiol 2004;44:
1328–33) © 2004 by the American College of Cardiology Foundationongestive heart failure (CHF) is a major and increasing incidence rate of 550,000 new cases a year and approxi-
m
c
i
k
t
w
e
p
rause of death and disability worldwide. In the U.S. alone,
he prevalence of heart failure is 4.6 million, with an
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ost of CHF is estimated at $56 billion a year, 70% of which
s due to hospitalization (2). One-third of patients with
nown CHF are admitted annually to the hospital, most of
hese through the emergency department (ED) (3).
See page 1334
Between 75% to 90% of all patients presenting to the ED
ith presumed CHF are admitted to the hospital, leading to
xorbitant costs and resource utilization (4). This high
ercentage of admissions is in part due to the absence of
eliable clinical or laboratory criteria that could aid in the
isposition decision. Although signs and symptoms of CHF
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September 15, 2004:1328–33 BNP Levels, ED Decision Making, and SOB Patientsay aid in the initial diagnosis of CHF, there is a poor
elationship between symptoms of CHF and both the
everity of cardiac dysfunction and prognosis.
B-type natriuretic peptide (BNP) levels have been used to
uccessfully aid in the diagnosis of CHF in patients pre-
enting with dyspnea (5–10). Because BNP levels correlate
ith both disease severity and prognosis (11–16) they
hould be of value in assisting in the appropriate manage-
ent and eventual disposition of CHF patients in the ED.
he purpose of the study was to illustrate the relationships
mong BNP levels within the diagnostic range, clinical
ecision making, and outcomes. If the magnitude of BNP
levation above the traditional diagnostic threshold of 100 is
rognostic, then it may be useful in deciding ultimate
dmission or discharge from the ED and other clinical
udgments.
ETHODS
tudy population. The study was approved by the institu-
ional review boards of participating REDHOT study
enters. The subject sample consists of a total of 464
atients at 10 sites who were enrolled from June 12, 2001 to
ebruary 3, 2003. Patients over the age of 18 years present-
ng to the ED with CHF and who received treatment in the
D or hospital admission for CHF were included. Current
yocardial infarction (MI) or acute coronary syndrome with
T-segment deviation of 1 mm, renal failure requiring
ialysis, or patients with a baseline BNP concentration of
100 pg/ml were excluded. Once written consent was
btained, a blood sample was collected for purposes of
easuring the patient’s BNP concentration. The study
oordinator ran these assays on-site at the point of care.
hysicians were told only whether or not the patient met
tudy criteria (BNP level 100 pg/ml).
After their initial clinical evaluation, physicians were
sked to rate the severity of disease (New York Heart
ssociation [NYHA] functional class I to IV) and whether
r not they believed the patient would ultimately be admit-
ed to the hospital (initial disposition). The research assis-
ant collected other data including elements from the
resent and past history, the physical examination, reports
f other blood tests, interpretations of chest X-rays, and
nterpretations of other diagnostic tests. Blood for BNP
evels was drawn every 3 h while in the ED and at the time
atients were either admitted to the hospital or discharged
Abbreviations and Acronyms
BNP  B-type natriuretic peptide
CHF  congestive heart failure
ED  emergency department
NYHA  New York Heart Association
REDHOT  Rapid Emergency Department Heart
failure Outpatient Trial
SOB  shortness of breathome. These data are not published because of marked Tttrition rates, as we lost 75% of our patients by 3 h owing
o the clinical decisions and subsequent patient disposition.
atient follow-up occurred at 30 and 90 days following
ither discharge from the ED or the hospital. Follow-up
ccurred via telephone interview, chart review, or by mail.
he events recorded were CHF-related visits (ED and
ospital admissions), and all-cause mortality.
easurement of BNP plasma levels. During initial eval-
ations, a blood sample was collected into tubes containing
otassium ethylene diamine tetra-acetic acid. The BNP was
easured using the Triage B-Type Natriuretic Peptide test
Biosite Inc., San Diego, California) (16). The Triage BNP
est is a fluorescence immunoassay for the quantitative
etermination of BNP in whole blood and plasma speci-
ens. The precision, analytical sensitivity, and stability
haracteristics of the system have been previously described
5,12,17,18). The BNP values were determined on-site
tilizing the point-of-care method with either whole blood
r plasma samples.
tatistical analysis. Continuous variables were summa-
ized with medians and quartiles (25th and 75th percentiles)
hile frequency counts were given for nominal variables. A
hi-square test was used to compare disposition decisions to
utcomes. The BNP levels were compared between dispo-
ition and outcome groups using Mann-Whitney U tests
nd among groups based on perceived severity (NYHA)
sing a Kruskal-Wallis test. Logistic regression was used to
valuate the power of BNP in combination with perceived
everity (NYHA functional class) and ED disposition for
redicting outcomes. A receiver-operating characteristic
ROC) curve was also calculated for prediction of death
rom BNP levels. Admitted patients were divided into two
roups based on BNP levels above and below 200 pg/ml to
tudy differences in outcome rates using chi-square tests.
his cutoff value for 200 pg/ml BNP was chosen retrospec-
ively based on statistical analyses and clinical outcomes.
his number had to be higher than the diagnostic value of
00 pg/ml but low enough to have high negative predictive
alue and still retain a significant number of patients to
ctually make a difference. Study power estimates were
omputed assuming that non-parametric tests are 95% as
owerful as their parametric counterparts (19). A medium
ffect size estimate of 0.5 standard deviation units was
elected (20). Using an alpha criterion of 0.05 and the
ample sizes for the comparisons of BNP levels in various
atients groups—discharged or admitted patients, dead or
live patients at 30 days, and dead or alive patients at 30
ays—yielded power estimates of 0.84, 0.45, and 0.78,
espectively.
ESULTS
he study cohort consisted of 464 patients (Table 1)
ncluding 46.1% females. The median age was 64 years, and
here was a preponderance of African Americans (63.4%).
he majority of patients presented to the ED with symp-
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BNP Levels, ED Decision Making, and SOB Patients September 15, 2004:1328–33oms suggestive of CHF, such as paroxysmal nocturnal
yspnea (59%) and orthopnea (78.4%). Concomitant chest
ain was reported in 30.7% of the cases. A history of CHF
as noted in 76.5% of cases and 42.0% had CHF-related
ospital visits in the previous three months. At the time of
nitial assessment in the ED, 67.8% of patients were
erceived to be either NYHA functional class III or IV
Table 1).
The overall hospitalization rate was 90.3%, even though
hysicians only intended to admit 68.3% upon initial
valuation (Table 2). There were 15 patients (3.2%) who
ied by the 30-day point and 36 patients (7.8%) expired by
he 90-day point. Events included all-cause mortality and
e-admission or ED visits for cardiac symptoms. Discharged
atients were more likely to experience an event (19 of 45 or
2.2%) than were admitted patients (110 of 425 or 25.9%)
y the 90-day follow-up (p  0.02).
Figure 1 shows the median BNP levels in patients as a
unction of perceived NYHA functional classification. The
NP levels did not differ significantly among the perceived
YHA functional classifications (p 0.124). This “discon-
ect” between the perceived severity and BNP level is
urther corroborated by Figure 2A, which shows that the
NP levels in patients who were discharged home were not
ignificantly different from those who were admitted to the
ospital (976 vs. 767 pg/ml, p  0.6). Figure 2 also shows
NP levels in relation to subsequent 30-day (Fig. 2B) and
0-day (Fig. 2C) mortality. The median BNP levels were
ignificantly higher in the deceased patient group as com-
ared to surviving patient group, using both 30-day and
0-day follow-up periods (2,096 pg/ml vs. 764 pg/ml, p 
.001, and 1,224 pg/ml vs. 727 pg/ml, p  0.001, respec-
ively).
Table 3 shows logistic regression analyses predicting 90
ay outcomes from BNP values along with ED disposition.
lthough the BNP level was a strong predictor of mortality
nd events (mortality, cardiac readmissions, and cardiac
isits) perceived severity (NYHA functional class ratings)
nd ED disposition (intention and actual) did not contrib-
te to the prediction of 90-day outcomes. Figure 3 shows
he ROC curve for BNP in predicting 90-day all-cause
ortality. The area under the ROC curve was 0.670 
.045 (p  0.001).
Because most patients were actually admitted, groups
ere formed to illustrate the outcomes for admitted patients
ith relatively low BNP levels. The difference between
dmitted patients with initial BNP levels above and below
00 pg/ml was examined in terms of ultimate outcome
Table 4). Among the admitted patients, 11% (43 patients)
ad BNP levels 200 pg/ml; 66% of these patients were
erceived to be NYHA functional classification III or IV.
he 90-day combined event rate (CHF visits or admissions
r all cause mortality) in the group of patients admitted with
NP200 pg/ml was 9% compared to those admitted with
NP200 pg/ml, which was 29% (p 0.006). The groupsable 1. Patient Characteristics
Variable (N)
Percentage or
Median
(Quartiles)
ale (%) (464) 53.9
ace (464)
Caucasian (%) 32.5
African-American (%) 63.4
Hispanic (%) 3.7
Asian (%) 0.4
ge (yrs) (464) 64 (51–76)
eight (inches) (451) 67 (65–70)
eight (lbs) (460) 190 (154–240)
ystolic BP (mm Hg) (462) 141 (121–166)
iastolic BP (mm Hg) (462) 81 (67–97)
eart rate (462) (beats/min) 92 (77–106)
xam variables
PND (400) 59.0
Elevated JVD 6 cm (413) 42.6
Orthopnea (439) 78.4
Pulmonary rales (456) 74.8
Wheezing (453) 27.6
Ascites (438) 9.6
Chest pain (460) 30.7
Ankle/peripheral edema (460) 75.0
S3 gallop (445) 19.6
Murmurs (445) 22.0
Diffuse and lateral PMI (445) 12.1
-ray variables
Increased heart size (458) 47.8
Interstitial edema (458) 50.7
Intra-alveolar edema (458) 19.8
Pleural effusion (458) 22.5
aboratory tests
Serum creatinine (mg/dl) (451) 1.2 (0.95–1.7)
Oxygen saturation (%) (437) 96 (93–98)
Max troponin I (ng/ml) (409) 0.3 (0.1–0.3)*
Max CK-MB (ng/ml) (305) 2.6 (1.6–4.9)
istory variables
Hypertension (456) 77.2
Diabetes (456) 40.6
Smoke 100 cig/yr (440) 39.5
Alcohol use (433) 23.1
COPD (442) 21.7
Asthma (450) 16.9
Myocardial infarction (437) 33.4
Angina (437) 33.4
Valve disease (406) 23.6
Atrial fibrillation (426) 25.4
Cardiac surgery (447) 29.1
CHF (446) 76.5
CHF-related hospital visits in last
3 months (407)
42.0
CHF-related hospital admissions
in last 3 months (405)
37.5
Perceived NHYA functional class
I 3.0
II 29.
III 45.0
IV 22.6
Owning the low discriminatory power of the old troponin I laboratory machine
specially in the lower ranges many patients had a level of 0.3. In actuality, only 11%
ere above normal cutoff levels used at that time (0.6 ng/ml).
BP  blood pressure; CHF  congestive heart failure; CK-MB  creatine
inase-MB fraction; COPD chronic obstructive pulmonary disease; JVD jugular
enous disease; NYHA  New York Heart Association; PMI  point of maximal
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September 15, 2004:1328–33 BNP Levels, ED Decision Making, and SOB Patientsid not differ significantly in terms of mortality alone (p 
.142).
ISCUSSION
he rising prevalence of CHF in the U.S. is not surprising.
eople are surviving MIs even with poor ventricular func-
ion, and newer medications allow patients with established
HF to live longer and more productive lives. What is
urprising is that up to 90% of CHF patients seen in the
Ds are admitted to the hospital (4). The resource utiliza-
ion for this group of patients is about 70% of the total costs
f heart failure (2). Comparatively, only about 37% to 60%
f patients seen with chest pain are admitted to the hospital
21). This is because there are excellent tools available to
elp triage and to prognosticate (e.g., electrocardiograms
nd troponins) in this group of patients, yet patients with
eart failure are usually admitted based on subjective eval-
ation of the patient’s symptoms.
It is surprising that BNP levels have thus far not been
sed to any large degree to help guide treatment and
isposition decisions in patients who present to the ED
ith CHF. The Breathing Not Properly multinational
tudy clearly demonstrated that BNP levels could aid a
hysician in making the diagnosis of heart failure, yet a
ecent editorial suggested that a competent physician does
ot need a BNP level to evaluate and treat patients with
Table 2. Initial Intent, Final Disposition, and
Intended
Disposition Actual Disposition D
Discharge (n  147) Discharged (n  39) 0
Admitted (n  108) 3
Admit (n  317) Discharged (n  6) 0
Admitted (n  311) 12
igure 1. Box and whisker plots of B-type natriuretic peptide (BNP) levels
y perceived New York Heart Association functional classification at time
f presentation at the emergency department. Medians are presented.
oxes illustrate upper and lower quartiles, and whiskers illustrate the 10thnd 90th percentiles. eart failure (22). The present study, however, shows that
erception of severity of CHF among ED physicians does
ot in fact correlate well with BNP levels; patients sent
ome from the ED actually showed a trend toward higher
NP levels than did those admitted, yet BNP levels were
uch stronger predictors of subsequent outcome. This gives
redence to the contention that a “disconnect” exists be-
ween the perceived severity of illness and BNP values, a
otion that should help decision-making. The present study
emonstrates that most admitted patients had perceived
YHA functional class III or IV; however, if the BNP level
as 200 pg/ml, the overall prognosis was excellent. Had
w-Up Events
Day Outcomes
atients Lost to
Follow-Up)
90-Day Outcomes
(12 Patients Lost to
Follow-Up)
Death or
Cardiac Visit Death
Death or
Cardiac Visit
) 10 (25.6%) 2 (5.1%) 17 (43.6%)
) 24 (22.2%) 9 (8.3%) 33 (30.6%)
) 1 (16.7%) 1 (16.7%) 2 (33.3%)
) 55 (17.4%) 24 (7.6%) 77 (24.3%)
igure 2. The B-type natriuretic peptide (BNP) distributions for various
atient groups. (A) The BNP levels versus the decision to discharge or
dmit the patient. (B) The BNP levels based on whether patients were alive
r dead at 30 days. (C) The BNP levels based on whether patients were
live or dead at 90 days Medians are presented. Boxes illustrate upper and
ower quartiles, and whiskers illustrate the 10th and 90th percentiles. EDFollo
30-
(7 P
eath
(0.0%
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BNP Levels, ED Decision Making, and SOB Patients September 15, 2004:1328–33aseline BNP levels been known, the absolute magnitude of
hange of BNP levels might have been even a better
redictor of outcome than the absolute BNP level. Further
ork should be done in this area.
oward triaging patients with CHF based on BNP
evels. The B-type natriuretic peptide for Acute Shortness
f breath EvaLuation (BASEL) study (23) randomized 425
atients presenting with dyspnea into BNP availability
ersus no BNP availability. The group that had BNP
vailable to them utilized less time in the emergency area
aking the diagnosis, had fewer admitted patients to the
ospital, and in those patients admitted to the hospital had
ess utilization of costly intensive care unit beds. The fact
igure 3. Receiver-operating-characteristic curve for B-type natriuretic
able 3. Logistic Regression
ogistic Regression to Predict 90-Day Mortality from BNP, NYHA
unctional Class, and Disposition Variables
Variable B S.E. p Value Exp(B)*
og BNP 1.537 0.42 0.001 4.531
YHA functional class 0.140 0.228 0.648 1.110
nitial intent 0.057 0.410 0.889 0.944
ctual disposition 0.231 0.681 0.735 1.260
ogistic Regression to Predict 90-Day Events (Mortality or Cardiac-
elated Admission or ED Visit) from BNP, NYHA Functional Class,
nd Disposition Variables
Variable B S.E. p Value Exp(B)*
og BNP 0.708 0.254 0.005 2.030
YHA functional class 0.091 0.137 0.507 0.913
nitial intent 0.368 0.243 0.130 0.692
ctual disposition 0.433 0.360 0.229 0.649
Exp(b) is the odds-ratio for the binary variables of intent and disposition, but this is
ot the case for log B-type natriuretic peptide (BNP) or New York Heart Association
NYHA) functional class.eptide in predicting 90-day mortality. AUC  area under the curve.hat there was a 26% reduction in total costs when BNP was
vailable suggests BNP’s utility in decision making.
It is not surprising that BNP levels are predictive of
rognosis. Cheng et al. (12) followed the course of 72
atients admitted with decompensated CHF with daily
NP levels and their relationship to 30-day readmis-
ion rates or death. Patients whose discharge BNP levels
ell 430 pg/ml had a reasonable likelihood of not being
eadmitted within the following 30 days. The data were
upported by a recent study by Bettencourt et al. (13)
ho found that failure of BNP levels to decline during the
ospitalization period is a predictor of death/rehospitalization,
nd that discharge levels 250 pg/ml predicted event-free
urvival. Recently, Harrison et al. (11) showed that BNP levels
easured in 325 patients presenting with dyspnea to the ED
ere highly predictive of cardiac events (cardiac death, ED
isit, or admission for a cardiac cause) over the ensuing six
onths. Patients with BNP levels 480 pg/ml had a 51%
ix-month cumulative probability of a CHF event. Alterna-
ively, patients with BNP levels 230 pg/ml had an excellent
rognosis, with only 2.5% incidence of death (cardiac and
on-cardiac), hospital admissions (cardiac), and repeat ED
isits for CHF.
The above studies along with the results of the present
rial strongly suggest that BNP levels can be utilized to help
ake disposition and management decisions that will ulti-
ately affect cost and outcomes. This is especially true in
atients with low BNP levels, who may not always need to
e admitted. For example, diagnosis-related group-127
ccounts for 80% of all CHF admissions. With 680,106
ospital admissions in 2001, and with a 5.27-day average
ength of stay and average cost of $5,414.68 per patient,
here is a total expenditure of $4.6 billion. Eleven percent of
he patients in this study were admitted with BNP levels
200 pg/ml. If BNP levels could decrease hospital admis-
ions by this percentage, there would be an estimated $500
illion savings. Thus, small improvements in disposition
ecisions may have a large impact on health care economics.
here is no way to know whether the decreased mortality
een in patient groups with BNP levels 200 pg/ml in this
tudy who were admitted was due to treatment or because
hey had less severe disease to begin with, even though the
atter is more likely owing to known correlation of BNP
evels to left ventricular filling pressure, NYHA functional
able 4. The Percentages of Various Outcomes for Admitted
atients Divided into Groups Based on a BNP Cut Point of
00 pg/ml
Admitted Patients
BNP
<200 pg/ml
(n  43)
BNP
>200 pg/ml
(n  364) p Value
YHA functional class
III and IV
66% 70% 0.598
ombined event rate 9% 29% 0.006
ortality 2% 9% 0.142
ombined events include cardiac-related admissions or visits, or all-cause mortality.
BNP  B-type natriuretic peptide; NYHA  New York Heart Association.
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September 15, 2004:1328–33 BNP Levels, ED Decision Making, and SOB Patientslassification, and severity of CHF. Thus, it is not possible
o recommend discharging a patient solely on the basis of a
NP level 200 pg/ml; rather, each patient should be
valuated on a per case basis. However, patients with BNP
evels 200 pg/ml had an excellent prognosis, even if CHF
as judged as severe.
Further studies might demonstrate that treatment deci-
ions could be based on changes in BNP levels with initial
reatment. Having baseline “dry” BNP levels available might
dd to the value of BNP levels in guiding treatment
ecisions.
tudy limitations. In this study, clinicians were blinded to
NP levels, so we were not able to prospectively assess the
bility to improve patient disposition based on BNP levels.
e cannot say what effect putting the patient in the hospital
ersus not hospitalizing the patient would have on ultimate
utcomes. Finally, we could not truly control for treatment
nterventions that occurred over the 90-day follow-up
eriod.
onclusions. In patients presenting to the ED with short-
ess of breath (SOB), there is a large “disconnect” between
he perceived severity of heart failure (as assessed by initial
isposition and NYHA functional class) and the BNP level.
ven in the setting where CHF severity is perceived as
evere, a low BNP level portends a favorable prognosis. This
tudy was not designed to assess whether patients with low
NP levels can be safely managed as an outpatient; rather,
t simply states that a rapid point-of-care BNP test in the
D can lead not only to accurate diagnosis of CHF but also
ight assist in the assessment of disease severity and
rognosis. The level of elevation of BNP appears to be a
etter reflection of 90-day outcomes than current disposi-
ion decisions and may be useful to stratify and triage
atients. This might decrease prolonged stays in the ED,
educe unnecessary hospitalizations, decrease inappropriate
ischarges home, and overall lead to better patient care.
merging clinical data will help further refine biomarker-
uided outpatient therapeutic and monitoring strategies
nvolving BNP.
eprint requests and correspondence: Dr. Alan Maisel, VAMC
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